Beam Therapeutics Inc. (BEAM) Stock
6 of the hedge funds AlphaScala tracks reported BEAM in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is ARK Invest's at $351.26M. Company insiders reported 0 open-market buys and 3 sales on SEC Form 4 in the 90 days to Nov 3, 2026.
Which hedge funds own BEAM?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| ARK Invest Cathie Wood | 10.23M | $351.26M | -16% |
| Marshall Wace | 479K | $16.44M | +244% |
| Renaissance Technologies Jim Simons (founder) | 445K | $15.27M | -13% |
| Duquesne Family Office Stanley Druckenmiller | 154K | $5.27M | NEW |
| D.E. Shaw David Shaw | 131K | $4.48M | NEW |
| Millennium Management Israel Englander | 34K | $1.18M | +54% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Beam Therapeutics Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 16, 26 | Evans John M. | CEO | SELL | 25.0K | $600K |
| Oct 15, 26 | Evans John M. | CEO | SELL | 25.0K | $589K |
| Oct 1, 26 | Cavanagh Bethany J | SVP, Finance and Treasurer | SELL | 187 | $5K |
| Jul 27, 26 | Simon Amy | Chief Medical Officer | SELL | 16.7K | $429K |
SEC Form 4 filings as of Nov 3, 2026
See cluster-buy signals across all tickers →BEAM price chart
Powered by TradingViewWhat does Beam Therapeutics Inc. do?
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through its pioneering base editing platform. This technology enables precise single-nucleotide changes in DNA without double-strand breaks, targeting serious genetic diseases. Key programs include BEAM-101, a base editor for sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle formulation for alpha-1 antitrypsin deficiency; and BEAM-301 for glycogen storage disease type Ia. The company also advances BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy integration, alongside liver-targeted initiatives like BEAM-304 for phenylketonuria. Beam Therapeutics employs a suite of delivery modalities, including electroporation, nonviral, and viral approaches, to support in vivo and ex vivo editing. Operating in the gene therapy and genome editing sector, it addresses unmet needs in hematology and liver genetic disorders. Founded in 2017 and headquartered in Cambridge, Massachusetts, with a manufacturing facility in Research Triangle Park, North Carolina, Beam Therapeutics focuses on innovative solutions for patients with debilitating conditions.